Search

Argenx SE

Gesloten

SectorGezondheidszorg

731.6 3.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

719.2

Max

744.2

Belangrijke statistieken

By Trading Economics

Inkomsten

455M

821M

Verkoop

1.5B

2.8B

K/W

Sectorgemiddelde

36.416

47.946

EPS

7.32

Winstmarge

29.79

Werknemers

1,863

EBITDA

70M

829M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-2.07% downside

Dividenden

By Acuity

Volgende Winsten

22 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.6B

51B

Vorige openingsprijs

728.18

Vorige sluitingsprijs

731.6

Nieuwssentiment

By Acuity

66%

34%

281 / 340 Rangschikking in Healthcare

Argenx SE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 okt 2026, 23:50 UTC

News

Constellation Brands Inc shares are modestly higher in after-market trading as analysts assess the company's valuation amid its focus on beer, wine, and spirits.

9 okt 2026, 23:25 UTC

News

Aon PLC declared a quarterly dividend of $0.820 per share, payable on November 13, 2026, and confirmed third-quarter earnings release for October 28, 2026.

9 okt 2026, 23:15 UTC

News

PayPal Holdings Inc is trading lower in after-hours activity, focusing on expanding credit offerings and Buy Now Pay Later services while planning share buybacks.

9 okt 2026, 23:15 UTC

News

Coca-Cola Consolidated Inc. declared a quarterly dividend of $0.25 per share, payable on November 6, 2026, to shareholders on record as of October 23, 2026.

9 okt 2026, 23:10 UTC

News

EnerSys receives a strong buy designation from Wall Street analysts, driven by optimism about AI infrastructure's impact on the data center sector.

9 okt 2026, 23:05 UTC

News

Truist Financial announces a $250K grant to support Gulf Coast communities' relief and recovery efforts ahead of Hurricane Isaias.

9 okt 2026, 23:05 UTC

News

JP Morgan reaffirms Overweight rating on Parker-Hannifin Corp, lowering its price target to $1.13K in a report released after the market closed.

9 okt 2026, 23:05 UTC

News

DICK'S Sporting Goods faces two class action lawsuits alleging securities fraud related to its business performance and disappointing financial results.

9 okt 2026, 23:01 UTC

News

Royal Caribbean Cruises Ltd is trading modestly lower in after-market hours, continuing a downward trend despite analysts suggesting the stock may be undervalued.

9 okt 2026, 23:01 UTC

Social Media
News

Perrigo Company PLC is reportedly under renewed takeover interest from an unidentified buyer, with speculation that CVC Capital may pursue an acquisition.

9 okt 2026, 23:01 UTC

News

Delta Air Lines Inc cut its guidance after missing third-quarter earnings and revenue estimates, with shares trading modestly lower in after-market hours.

9 okt 2026, 23:01 UTC

News
Social Media

Verizon shares are trading higher in after-market hours, despite reports of its worst trading day since 2002 amid competitive pressures from SPCX and T-Mobile's decline.

9 okt 2026, 22:50 UTC

News
Social Media

Star Bulk Carriers announces a partnership with Hermes World Maritime and renews equity offerings with Deutsche Bank for $41.37M and Jefferies for $75M.

9 okt 2026, 22:50 UTC

News

GoDaddy faces a class action lawsuit from Pomerantz LLP alleging securities fraud and unlawful business practices, encouraging affected shareholders to join by October 20, 2026.

9 okt 2026, 22:21 UTC

News

CareTrust REIT, Inc. released its sixth annual Corporate Sustainability Report, highlighting advancements in sustainability initiatives and adherence to ISS ESG Prime status.

9 okt 2026, 22:20 UTC

News

Mesa Laboratories Inc announced a quarterly dividend of $0.16 per share, payable on December 15, 2026, to shareholders of record on November 30, 2026.

9 okt 2026, 21:01 UTC

Correlated Moves
News

USD/PLN is gaining and remains above its 20-day moving average, near the upper end of its one-month range, despite earlier pulling back from a session high.

9 okt 2026, 20:41 UTC

News
Correlated Moves

USD/SEK is modestly higher, supported by an increase in the U.S. Baker Hughes total rig count to 603 from 598.

9 okt 2026, 20:40 UTC

News

Standard Motor Products announces CFO Nathan R. Iles' resignation effective October 30, 2026, with James J. Burke as interim CFO, prompting a decline in after-market trading.

9 okt 2026, 20:07 UTC

News

United Parcel Service Inc shares are higher, supported by plans to hire 100k seasonal workers and new services aimed at enhancing parcel security and pricing power.

9 okt 2026, 20:07 UTC

News
Correlated Moves
Social Media

Microsoft introduces its new AI model, Microsoft-Decision-1, which reportedly makes decisions 35 times faster than OpenAI's GPT-6 Sol, as announced by CEO Satya Nadella.

9 okt 2026, 20:07 UTC

News

Baird analyst Andrew Wittmann lowered Construction Partners Inc's price target to $115.00 from $141.00 while maintaining an Outperform rating.

9 okt 2026, 20:07 UTC

News

Barclays analyst Michael Lonegan lowers Idacorp's price target to $149.00 from $162.00 while maintaining an Overweight rating.

9 okt 2026, 20:07 UTC

Macro Event
News

Evercore ISI maintains its Underperform rating on Franklin Resources, lowering the price target to $35, contributing to a decline in the stock.

9 okt 2026, 20:07 UTC

Macro Event
News

Dollar General shares advanced, buoyed by broader market gains, despite earlier pulling back from a session high, amid a significant drop in consumer sentiment.

9 okt 2026, 20:07 UTC

News

UBS reaffirms Buy rating on Biogen Inc and raises price target to $270 from $240, while CCB International initiates coverage with an Outperform rating.

9 okt 2026, 20:07 UTC

Correlated Moves
News
Social Media

Viking Therapeutics is seeing increased interest amid reports of a potential bidding war, with speculation about suitors including LLY and positive momentum in the biotech sector.

9 okt 2026, 20:07 UTC

News

Schrodinger Inc rebounds amid volatility, supported by a $1.8 billion Biohub partnership announced by the White House focusing on AI-ready biological data.

9 okt 2026, 20:07 UTC

Social Media
News

Raymond James initiated coverage on Kymera Therapeutics Inc with an Outperform rating and set a price target of $140.

9 okt 2026, 20:07 UTC

Social Media
Event
News

Marvell Technology Inc. shares advanced after Stifel reiterated a Buy rating and raised its price target to $370, supported by increased fiscal year 2028 revenue guidance.

Peer Vergelijking

Prijswijziging

Argenx SE Prognose

Koersdoel

By TipRanks

-2.07% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 438.33 EUR  -2.07%

Hoogste 545 EUR

Laagste 223 EUR

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Argenx SE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

5

Buy

0

Hold

1

Sell

Sentiment

By Acuity

281 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.